Floatz logo

Therapeutic Asset Ratings

2,003 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Nivolumab
Stage IV Bladder Cancer AJCC v8
M.D. Anderson Cancer CenterP2B (63)
TACROLIMUS
Burkitt Lymphoma
M.D. Anderson Cancer CenterP2B (63)
Venetoclax
T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer CenterP2B (63)
(+)-VINCRISTINE
Microsatellite Stable
M.D. Anderson Cancer CenterP2B (63)
(+)-VINCRISTINE
Philadelphia Chromosome Positive
M.D. Anderson Cancer CenterP2B (63)
(+)-VINCRISTINE
Recurrent Malignant Uterine Corpus Neoplasm
M.D. Anderson Cancer CenterP2B (63)
Cladribine
Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer CenterP2/3B (63)
Decitabine
T Lymphoblastic Leukemia/Lymphoma
M.D. Anderson Cancer CenterP3B (62)
Decitabine
T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer CenterP3B (62)
Irinotecan
Kidney Cancer
M.D. Anderson Cancer CenterP3B (62)
(+)-VINCRISTINE
Kidney Cancer
M.D. Anderson Cancer CenterP3B (62)
ag-120
Myeloproliferative Neoplasm
M.D. Anderson Cancer CenterP2B (62)
Allopurinol
Leukemia
M.D. Anderson Cancer CenterP2B (62)
Atezolizumab
Female Reproductive Organ Cancer
M.D. Anderson Cancer CenterP2B (62)
Atezolizumab
Thoracic Cancer
M.D. Anderson Cancer CenterP2B (62)
Benadryl
Myelodysplastic Syndromes
M.D. Anderson Cancer CenterP2B (62)
Bortezomib
Carcinoma Of Urethra
M.D. Anderson Cancer CenterP2B (62)
CABAZITAXEL
Prostate Carcinoma
M.D. Anderson Cancer CenterP2B (62)
cc-5013
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP2B (62)
cc-5013
Leukemia
M.D. Anderson Cancer CenterP2B (62)
Cediranib
Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer CenterP2B (62)
Cladribine
Leukemia
M.D. Anderson Cancer CenterP2B (62)
Eloxatin
Refractory Cancer
M.D. Anderson Cancer CenterP2B (62)
gsk1120212
Cutaneous Melanoma
M.D. Anderson Cancer CenterP2B (62)
Humax-Cd20
Acute Lymphoblastic Leukemia
M.D. Anderson Cancer CenterP2B (62)
Showing 201 to 225 of 2,003 assets
PreviousPage 9 of 81Next